Home Articles List Article Information
Iranian Journal of Pharmaceutical Research
Journal Archive
Volume Volume 17 (2018)
Volume Volume 16 (2017)
Volume Volume 15 (2016)
Volume Volume 14 (2015)
Volume Volume 13 (2014)
Volume Volume 12 (2013)
Volume Volume 11 (2012)
Volume Volume 10 (2011)
Volume Volume 9 (2010)
Volume Volume 8 (2009)
Volume Volume 7 (2008)
Volume Volume 6 (2007)
Volume Volume 5 (2006)
Volume Volume 4 (2005)
Volume Volume 3 (2004)
Volume Volume 2 (2003)
Volume Volume 1 (2002)
Habibi Asl, B., Hassanzadeh, K. (2010). The effect of magnesium and bromocriptine on morphine induced dependence and withdrawal symptoms in mice. Iranian Journal of Pharmaceutical Research, Volume 3(Supplement 1), 47-47.
B Habibi Asl; K Hassanzadeh. "The effect of magnesium and bromocriptine on morphine induced dependence and withdrawal symptoms in mice". Iranian Journal of Pharmaceutical Research, Volume 3, Supplement 1, 2010, 47-47.
Habibi Asl, B., Hassanzadeh, K. (2010). 'The effect of magnesium and bromocriptine on morphine induced dependence and withdrawal symptoms in mice', Iranian Journal of Pharmaceutical Research, Volume 3(Supplement 1), pp. 47-47.
Habibi Asl, B., Hassanzadeh, K. The effect of magnesium and bromocriptine on morphine induced dependence and withdrawal symptoms in mice. Iranian Journal of Pharmaceutical Research, 2010; Volume 3(Supplement 1): 47-47.

The effect of magnesium and bromocriptine on morphine induced dependence and withdrawal symptoms in mice

Article 82, Volume 3, Supplement 1, Autumn 2004, Page 47-47  XML
Authors
B Habibi Asl; K Hassanzadeh
Abstract
The aim of this study was to investigate the effects of magnesium as a N-Methyl–D-Aspartate (NMDA) receptor Antagnist and bromocriptine as a dopamine receptor agonist on morphine dependence and withdrawal symptoms. In the present study different groups of mice were received morphine (50 mg/kg, i.p.) for four days and on fourth day 1.5 hour after the last morphine administration they received different doses of magnesium (40, 60, 80 mg/kg, i.p.) or bromocriptine (5, 10, 20 mg/kg, i.p.) and 0.5 hour later naloxan (4 mg/kg, i.p.) was administrated and withdrawal symptoms was assessed during 30 min. This study shows that administration of magnesium or bromocriptine has decreased the morphine-dependence and withdrawal symptoms significantly.
Magnesium can prevent the development of morphine tolerance and dependence. The mechanism of this effect is related to the property of magnesium to block the NMDA receptors. On the other hand, bromocriptine decreased the withdrawal symptoms and this mechanism may be related to dopamine agonist and ?2 agonist behavior of bromocriptine.
Statistics
Article View: 2,233
PDF Download: 11